We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+31.56%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.85B
AUM Growth
+$887M
Cap. Flow
+$249M
Cap. Flow %
6.46%
Top 10 Hldgs %
72.18%
Holding
61
New
10
Increased
9
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$80.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$79.9M
5
TNGX icon
Tango Therapeutics
TNGX
+$40M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$131M
2
SWTX
SpringWorks Therapeutics
SWTX
+$80M
3
RLAY icon
Relay Therapeutics
RLAY
+$35M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$30.2M
5
SLRN
ACELYRIN
SLRN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
26
Nuvation Bio
NUVB
$2.32B
$29M 0.75%
19,209,643
– –
PHVS icon
27
Pharvaris
PHVS
$2.37B
$25.2M 0.66%
+900,000
New +$18.2M
NGNE icon
28
Neurogene
NGNE
$691M
$24.6M 0.64%
+1,271,342
New +$18.2M
LENZ
29
LENZ Therapeutics
LENZ
$179M
$22.4M 0.58%
1,219,778
– –
AVIR icon
30
Atea Pharmaceuticals
AVIR
$386M
$21.3M 0.55%
6,995,861
– –
OVID icon
31
Ovid Therapeutics
OVID
$439M
$19.7M 0.51%
6,117,400
– –
SYRE icon
32
Spyre Therapeutics
SYRE
$8.69B
$19.1M 0.5%
887,076
+687,080
+344% +$9.47M
VERV
33
DELISTED
Verve Therapeutics
VERV
$17.4M 0.45%
+1,250,000
New +$15.5M
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
$12.2M 0.32%
+1,115,022
New +$11.1M
GOSS icon
35
Gossamer Bio
GOSS
$97.5M
$8.39M 0.22%
9,195,404
– –
MORF
36
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.1M 0.16%
211,262
-1,268,928
-86% -$30.2M
PRQR icon
37
ProQR Therapeutics
PRQR
$244M
$5.9M 0.15%
2,980,016
– –
ATRA icon
38
Atara Biotherapeutics
ATRA
$69.5M
$5.16M 0.13%
+402,682
New +$9.39M
ALGS icon
39
Aligos Therapeutics
ALGS
$25.2M
$4.24M 0.11%
255,579
+97,645
+62% +$1.68M
RVMD icon
40
Revolution Medicines
RVMD
$40B
$3.8M 0.1%
132,579
-5,445,284
-98% -$131M
HOOK
41
DELISTED
HOOKIPA Pharma
HOOK
$3.72M 0.1%
459,502
– –
GBIO
42
DELISTED
Generation Bio
GBIO
$3.38M 0.09%
204,687
– –
NGM
43
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.05M 0.05%
2,385,873
-4,049,645
-63% -$3.56M
ALLK
44
DELISTED
Allakos
ALLK
$2.04M 0.05%
748,900
– –
TYRA icon
45
Tyra Biosciences
TYRA
$1.85B
$1.9M 0.05%
+137,014
New +$1.77M
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$953M
$1.81M 0.05%
198,480
-501,520
-72% -$4.32M
PMVP icon
47
PMV Pharmaceuticals
PMVP
$62.9M
$1.76M 0.05%
+566,879
New +$1.5M
NUVB.WS
48
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.45M 0.04%
963,333
– –
NAMSW icon
49
NewAmsterdam Pharma Warrant
NAMSW
$87.4M
$745K 0.02%
66,665
– –
SRZNW icon
50
Surrozen Inc Warrant
SRZNW
$75.6K
$627K 0.02%
66,665
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2023 Portfolio in Review

As of Q4 2023, EcoR1 Capital held 61 positions worth $3.85B, up 30% from $2.96B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital deployed $249M of net new capital in Q4 2023, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was argenx: 300,997 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $131M trimmed.

  • EcoR1 Capital's largest Q4 2023 buy was argenx: 300,997 shares worth $115M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $92.7M increase.
  • EcoR1 Capital's biggest Q4 2023 reduction was Revolution Medicines, cutting an estimated $131M.
  • EcoR1 Capital fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $80M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $3.85B portfolio in Q4 2023.
  • EcoR1 Capital opened 10 new positions and closed 10 in Q4 2023.
  • EcoR1 Capital's portfolio value rose 30% quarter-over-quarter to $3.85B.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.